Strong commercial performance in 2025: Annual Recurring Revenue (ARR) of €108.0m (+8.8% as reported on 31 December 2025) and full-year revenue of €236.5m (+9.1% as reported)

Core Insights - Equasens Group reported strong commercial performance in 2025, with Annual Recurring Revenue (ARR) reaching €108.0 million, an increase of 8.8% year-on-year, and full-year revenue of €236.5 million, up 9.1% [2][8]. Financial Performance - The second half of 2025 showed particularly strong growth, with reported revenue growth of 10.8%, aligning with company guidance [3]. - Full-year revenue breakdown by quarter shows: - Q1: €57.0 million (+6.9%) - Q2: €58.9 million (+7.8%) - Q3: €56.2 million (+12.1%) - Q4: €64.3 million (+9.7%) [4]. - Newly consolidated entities, including Calimed and Novaprove, contributed €4.2 million to full-year revenue [4]. Business Segments - Revenue by business segment for 2025: - Systems and equipment: €94.1 million (+11.9%) - Maintenance and subscriptions: €105.1 million (+6.8%) - Software and services: €37.3 million (+8.8%) [9]. - The Pharmagest division reported revenue of €172.2 million (+5.3%) and the Axigate Link division reached €37.6 million (+17.0%) [14]. Strategic Acquisitions - Equasens Group acquired an 80% stake in EREVO, enhancing its position in the digital continuing education market for healthcare [5]. - Recent acquisitions have contributed significantly to revenue growth, particularly in the recurring revenue segment [11][24]. Market Position and Outlook - The company aims to strengthen its leadership in the European digital health solutions market, focusing on technological innovation and interoperability [27]. - The rollout of new software solutions and functionalities, including artificial intelligence, is expected to drive future growth [28].